Hormone Therapy Timing & Heart Risk
study3_post08  |  image: study3_post08_clinical.png
------------------------------------------------------------------------

ON THE IMAGE
What the major studies actually showed

CAPTION
Three trials that are often cited against each other actually fit together once timing is accounted for.

DOPS enrolled recently postmenopausal women and found cardiovascular benefit. ELITE tested timing directly and found benefit only in the early group. WHI enrolled women aged 50–79, tested one oral formulation, and found increased risk.

Different populations, different formulations, different answers.

Questions about what this means for you? Call [Practice Name] at [Phone] or book at [Booking Link].

Educational content, not medical advice — individual results and risks vary.

HASHTAGS
#menopause #womenshealth #hearthealth #hormonetherapy #midlifewomen

SUPPORTING EVIDENCE
Table 1 trial summaries: DOPS composite reduction; ELITE early initiation slowed carotid IMT progression; WHI increased coronary events, stroke and VTE.
